NEW YORK, April 21, 2015 /PRNewswire/ — IntelliQuit™, the world's first smartphone breathalyzer for smokers, was selected to present as a finalist at the American Heart Association's Health Sciences Innovation – Investment Forum in New York City on Wednesday April 22.
Photo – http://photos.prnewswire.com/prnh/20150421/199989
Thirty percent (30%) of all cardiovascular disease is caused by smoking. The IntelliQuit™ device and mobile app ecosystem is the amalgamation of technologic sophistication and clinical expertise. Research demonstrates that comprehensive one-on-one tobacco treatment can reduce state-wide hospitalizations from acute myocardial infarctions and coronary artery disease by 40 to 50 percent. The cardiovascular health benefits precipitated by tobacco abstinence were achieved with as little as a 10% reduction in smoking rates.
The IntelliQuit™ device, smaller and weighing less than a butane lighter, informs smokers of their biochemical tobacco consumption via expired breath analysis. Linked via Bluetooth to the smoker's smart phone IntelliQuit provides smokers with interactive behavioral biofeedback, data driven coaching and treatment plans to help quitting the way they started: one puff, one breathe at a time.
Smoking kills 500,000 Americans every year. While 70% of smokers (32 million) want to quit almost 90% prefer to quit smoking gradually rather than abruptly. IntelliQuit's biosensor and ecosystem measures that smoker's biochemical tobacco consumption and assists the smoker in gradual cessation. Like any behavior change, a step at a time is easier than all at once. IntelliQuit confirms progress and increases quit rates. Independent studies demonstrate than a 1% reduction in expired breath carbon monoxide increases the odds of quitting 3 to 4 percent.
To learn more about IntelliQuit™'s American Heart Association Innovation Challenge Project http://www.medstartr.com/projects/578-intelliquit and www.MyLungTest.com
For more information contact:
Tracy Miceli
201-214-3776